OREXIGEN THERAPEUTICS INC | 4,775 Euro | +0,097 +2,07 % | |
| WKN: A0MQ04 ISIN: US6861641040 Ticker-Symbol: JXS | Frankfurt | 19.06.13 | 15:32 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 19.06. | American Medical Association Decision Can Boost Arena, Vivus, And Orexigen | 3 | Seeking Alpha | |
| 15.06. | 19.1% Return Seen to Date on SmarTrend Orexigen Therapeutics Call | 1 | SmarTrend | |
| 07.06. | Orexigen Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | |
| 07.06. | Orexigen Therapeutics Has Returned 16.2% Since SmarTrend Recommendation | - | SmarTrend | |
| 31.05. | Orexigen Therapeutics Has Returned 22.6% Since SmarTrend Recommendation | 1 | SmarTrend | |
| 30.05. | Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference | 50 | PR Newswire | |
| SAN DIEGO, May 30, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Jefferies 2013 Global Healthcare Conference... Mehr lesen zu: Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference | ||||
| 30.05. | Is Novo A Threat To Arena, Vivus, And Orexigen? | 4 | Seeking Alpha | |
| 28.05. | Orexigen Therapeutics Makes a Move: Up 4.7% | 1 | SmarTrend | |
| 24.05. | Possible Bearish Inside Day Candle Pattern Detected for Orexigen Therapeutics | 1 | SmarTrend | |
| 22.05. | Orexigen Therapeutics' CEO Presents at 2013 UBS Global Healthcare Services Conference (Transcript) | 2 | Seeking Alpha | |
| 20.05. | Orexigen Therapeutics Earnings Review: 12 Days after Announcement Shares Up 0.7% | 5 | SmarTrend | |
| 17.05. | Orexigen Therapeutics to Present at the UBS Global Healthcare Conference | 55 | PR Newswire | |
| SAN DIEGO, May 17, 2013 /PRNewswire/ --Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York.... Mehr lesen zu: Orexigen Therapeutics to Present at the UBS Global Healthcare Conference | ||||
| 16.05. | Orexigen Therapeutics' Management Presents at Bank of America Merrill Lynch Health Care Conference - Transcript | - | Seeking Alpha | |
| 10.05. | Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference | 66 | PR Newswire | |
| SAN DIEGO, May 10, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2013 Health... Mehr lesen zu: Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference | ||||
| 09.05. | Orexigen Therapeutics, Inc. - 10-Q, Quaterly Report | 1 | SEC Filings | |
| 09.05. | Orexigen Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript | 2 | Seeking Alpha | |
| 08.05. | Orexigen Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | |
| 08.05. | Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013 | 33 | PR Newswire | |
| SAN DIEGO, May 8, 2013 /PRNewswire/ --Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for... Mehr lesen zu: Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013 | ||||
| 08.05. | Is Orexigen Therapeutics Burning Too Much Cash? | 2 | Motley Fool | |
| 07.05. | SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc. | 44 | PR Newswire | |
| NEW YORK, May 7, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Orexigen Therapeutics, Inc. (NasdaqGS: OREX), and its Board of Directors, in connection with possible claims of breaches... Mehr lesen zu: SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc. | ||||
Seite: 1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| CELL THERAPEUTICS | 0,944 | +2,72 % | Cell Therapeutics Says EXTEND Analyses Evaluate Efficacy Of Single Agent PIXUVRI |
| VIVUS | 10,799 | +3,19 % | Vivus Crosses Above its 10-day MA |
| PAION | 0,662 | +0,46 % | Paion: 10 Prozent Aufschlag |
| AMGEN | 76,00 | +1,06 % | Amgen Award For Science Teaching Excellence Honors Outstanding Teachers |
| BIOGEN IDEC | 156,25 | +0,55 % | Iconix Brand Group, Ralph Lauren, DaVita HealthCare Partners, Myriad Genetics and Biogen Idec highlighted as Zacks Bull and Bear of the Day |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von